The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Fitzpatrick Alexander A since 2018.
This trader's CIK number is 1398595.
At the time of last reporting, Fitzpatrick Alexander A was the Chief Legal Officer of Ars Pharmaceuticals, Inc.. (stock ticker symbol SPRY).
Also see all insider trading activities at Ars Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2021 | EVFM | 35,000 | $19,975 | 0 | $0 | 0 | $0 |
| 2020 | EVFM | 9,090 | $19,998 | 0 | $0 | 0 | $0 |
| 2018 | EVFM | 5,000 | $11,035 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2026 | SPRY | 0 | $0 | 3,355 | $33,550 | 0 | $0 |
| 2025 | SPRY | 0 | $0 | 102,969 | $1,451,553 | 100,000 | $558,000 |
| 2023 | SPRY | 86,258 | $319,954 | 0 | $0 | 0 | $0 |
1. Evofem Biosciences, Inc. (EVFM)
2. Ars Pharmaceuticals, Inc. (SPRY)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-12-20 | EVFM | Buy | 25,000 | .39 | 9,725 |
| 2021-06-10 | EVFM | Buy | 10,000 | 1.02 | 10,250 |
| 2020-11-17 | EVFM | Buy | 9,090 | 2.20 | 19,998 |
| 2018-08-20 | EVFM | Buy | 4,500 | 2.20 | 9,900 |
| 2018-08-21 | EVFM | Buy | 500 | 2.27 | 1,135 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-06-12 | SPRY | Sale | 3,355 | 10.00 | 33,550 |
| 2025-05-20 | SPRY | Option Ex | 100,000 | 5.58 | 558,000 |
| 2025-05-20 | SPRY | Sale | 102,969 | 14.10 | 1,451,553 |
| 2023-09-28 | SPRY | Buy | 40,000 | 3.62 | 144,960 |
| 2023-09-29 | SPRY | Buy | 46,258 | 3.78 | 174,994 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Fitzpatrick Alexander A (Chief Legal Officer of Ars Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.